- Exchange: Frankfurt
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Novelos Therapeutics Inc
+ Add to WatchlistNV4N:GR
0.260 EUR 0.044 14.47%As of 02:23:58 ET on 05/24/2013.
Snapshot for Novelos Therapeutics Inc (NV4N)
| Open: | 0.306 | Day's Range: | 0.260 - 0.306 | Volume: | 0 |
|---|---|---|---|---|---|
| Previous Close: | 0.304 | 52wk Range: | 0.220 - 1.242 | 1-Yr Rtn: | -74.00% |
Key Statistics for NV4N
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. DAX | - |
| Earnings Per Share (ttm) | - |
| Est. EPS (12/2013) | - |
| Est. PEG Ratio | - |
| Market Cap (M EUR) | 0.00 |
| Shares Outstanding (M) | 0.00 |
| 30 Day Average Volume | 165 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/09/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for NV4N
Company Profile & Key Executives for NV4N
Novelos Therapeutics, Inc. is a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer. Novelos' three cancer-targeted compounds, which are selectively taken up and retained in cancer cells and cancer stem cells, versus normal cells, are being developed to find, treat and follow cancer anywhere in the body.
| Harry S PalminPresident/CEO | Jamey P WeichertChief Scientific Officer |
| Joanne M ProtanoVP/CFO/Treasurer | Christopher J PazolesVP:Research & Development |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
NV4N News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page